International Journal of Clinical & Medical Imaging | OMICS International | Editorial Board
Home  |  Journals  |  Conferences |   Membership  |   FAQ's
Join  |  Contact  |   Sitemap  |                
OMICS Group Inc

International Journal of Clinical & Medical Images

ISSN: 2376-0249 Open Access

Butterfly Glioma Involving Splenium of Corpus Callosum

Other Art Works

Image 01 Image 02
Image 03 Image 04
Image 05 Image 06
Image 07 Image 08
Image 09 Image 10
Image 11 Image 12
Image 13 Image 14
Image 15 Image 16
Image 17 Image 18
Image 19 Image 20
Image 21 Image 22
Image 23 Image 24
Image 25 Image 26
Image 27 Image 28
Image 29 Image 30

61 year old male presented with headache, nausea, vomiting, disorientation and ataxia. MRI brain revealed a heterogenous solitary mass suggestive of glioblastoma multiforme involving the splenium of the corpus callosum and crossing the midline, measuring 5.4 cm in transverse, 3.6 cm in antero-posterior, 3.3 cm in craniocaudal dimensions (Figures 1 and 2). Surrounding peritumoural edema was evident. Glioblastoma multiforme (WHO grade IV) was subsequently confirmed on biopsy and deemed inoperable by the neurosurgical team. The patient’s performance status precluded palliative chemotherapy. He was referred to the specialist palliative care inpatient unit to facilitate the planned ten fractions of palliative whole brain radiotherapy in conjunction with steroid therapy. Unfortunately his condition deteriorated further and he was unable to complete the planned protocol. Glioblastoma multiforme is the most common primary intra-axial malignancy, accounting for 12-15% of all intracranial neoplasms. It generally originates in the cerebral white matter and spreads along the corpus callosum in a “butterfly” pattern to the opposite side. The corpus callosum is divided into rostrum, genu, body, isthmus, and posteriorly, the splenium. The fibres in the splenium connect posterior parietal, medial occipital, and medial temporal cortexes. The splenium is primarily affected in this case and represents the least common are of callosal involvement (10%). Prognosis is poor. The median survival time from the time of diagnosis without any treatment is 3-6 months, but with treatment survival of 1-2 years is common. Increasing age (>60 years of age), abnormal brain function, or significant disabilities carry a worse prognostic risk.